賽諾醫療(688108.SH)與巴泰醫療簽署戰略合作框架協議
格隆匯11月10日丨賽諾醫療(688108.SH)公佈,公司與巴泰醫療經友好磋商,於2020年11月8日在浙江省杭州市達成戰略合作意向並簽署《戰略合作框架協議》。
根據《框架協議》,巴泰醫療將委任賽諾醫療作為其冠脈產品(包括:紫杉醇洗脱PTCA球囊擴張導管、冠脈刻痕球囊導管、冠脈一次性使用導管鞘組、冠脈一次性使用導引導管、冠脈一次性使用造影導管等產品)市場營銷的獨家戰略合作伙伴,在中華人民共和國境內及海外部分國家經營和銷售巴泰醫療的特定產品,賽諾醫療將為巴泰醫療的產品開放銷售渠道資源及市場資源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.